logo
Plus   Neg
Share
Email

Array BioPharma Enters Into Clinical Trial Collaboration Agreement With Pfizer

Array BioPharma Inc. (ARRY) said it has entered into a clinical trial collaboration agreement with Pfizer Inc. (PFE) to investigate the safety and efficacy of several novel anti-cancer combinations.

This includes Array's MEK inhibitor, binimetinib, with Pfizer's investigational PARP inhibitor talazoparib, and avelumab, a human anti-PD-L1 IgG1 monoclonal antibody.

The two companies entered into this collaboration to explore the potential benefits of combining molecularly targeted therapeutics with the body's innate cancer-fighting abilities using immunotherapy.

Under the terms of the agreement, Array and Pfizer will collaborate on a Phase 1b clinical trial to explore a series of novel combinations, investigating the safety and efficacy of the combination of binimetinib, avelumab and talazoparib across various tumor types.

The companies expect a multi-arm clinical trial to establish recommended doses of different regimens combining the drugs. Initially the focus will be in non-small cell lung cancer or NSCLC and pancreatic cancer, and additional indications will be explored at a later stage.

The study is expected to begin by the third quarter of 2018, and results will be used to determine optimal approaches to further clinical development of these combinations.

Under the collaboration agreement, the trial will be sponsored and funded by Pfizer, with Array providing binimetinib supply.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Delta Air Lines will resume non-stop flights between the U.S. and India next year, almost a decade after it exited the Indian market. The airline said Thursday that its decision to resume non-stop flights from the U.S. to India follows agreements between the U.S. and the governments of the United Arab Emirates and Qatar to address the issue of government subsidies provided to state-owned carriers. Mortgage rates continued their upward trend this week and hit a seven-year high, even as housing demand remained robust. According to data released Thursday by mortgage finance provider Freddie Mac, the 30-year fixed-rate mortgage rose to 4.66 percent in the week ending May 24, from 4.61 percent in the prior week and 3.95 percent a year ago. This is also the highest level since May 5, 2011. In a signing ceremony for a bill rolling back regulations on small and medium-sized banks, President Donald Trump suggested Thursday he would also consider cutting regulations on larger financial institutions. Trump claimed complex and costly regulations implemented following the 2008 financial crisis...
Follow RTT